Accipiter Biosciences

Developer of de novo protein therapies for complex diseases treatment

placeSeattle, Washington, United States calendar_todayFounded 2023 language accipiterbio.com

Social engagement

Social engagement: 1.3K social following, 3 posts in the last 12 months — below the industry typical range.

Investor mix

8 investors on record; lead investors include Takeda, Flying Fish Ventures.

Investor typeCountShare
Venture capital450%
Other / undisclosed450%
Coming soon